戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1  syndrome), but the mechanism underlying these associations is unknown.
2                                 The etiology of isolated BA is unknown, with evidence for infectious, environmental, and
3 d and integrated into the brain to drive migratory behavior is unknown.
4 fter chromosome condensation and nuclear envelope breakdown is unknown.
5 udies have been published and the true PeV infection burden is unknown.
6 he knowledge of the authors the association with tau burden is unknown.
7                              Hitherto, their role in cancer is unknown.
8 havior, but how this signal is received by epithelial cells is unknown.
9 the functional consequence of LEC priming of CD8(+) T cells is unknown.
10         Whether premature menopause is associated with CHIP is unknown.
11 ation and function of this mark within the infectious cycle is unknown.
12 associative brain regions is established during development is unknown.
13 ting RV hypertrophy and failure in congenital heart disease is unknown.
14 ceptive placebos represent genuine psychobiological effects is unknown.
15 -TP exposure, and therefore compromise prevention efficacy, is unknown.
16  acetylation, but how SIRT6 is able to accomplish this feat is unknown.
17                                        The prevalence of FH is unknown in 90% of countries in the world.
18 unction in chronic liver injury sequelae, such as fibrosis, is unknown.
19 eptor; however, its impact on pancreatic beta-cell function is unknown.
20 ism for this tolerance-inducing effect of alcohol, however, is unknown.
21 ion depends on bacteria-specific or tumor-specific immunity is unknown.
22 nduced pulmonary congestion carries prognostic implications is unknown.
23 the consequences of plant species composition for infection is unknown.
24 lying IOP elevation associated with intravitreal injections is unknown.
25  and UL48, but the functional relevance of this interaction is unknown.
26                                                          It is unknown how coexisting cells differ in their response to n
27                                                          It is unknown whether concomitant AS-CA has worse outcomes or re
28                                                          It is unknown whether cone beam computed tomography (CBCT) image
29                                                          It is unknown, however, how manganese accumulates in dopaminergi
30  cells (cDC1s and cDC2s, respectively) is well accepted; it is unknown how robust this dichotomy is under inflammatory co
31 resulting burns remain sensitive to touch for weeks, but it is unknown whether calves experience ongoing, non-evoked pain
32                                                 However, it is unknown which, if any, of these NET-affiliated proteins is
33  the hands is associated with rheumatoid arthritis (RA), it is unknown whether tenosynovitis of the forefoot is associate
34 alue of mucosal rejection assessment for patient management is unknown.
35                                     The role of TET2 in PAH is unknown.
36  infants, but whether IGF-1 treatment can prevent BPD or PH is unknown.Objectives: To evaluate whether postnatal treatmen
37 ts role in placentally related disorders of human pregnancy is unknown(3).
38 d an inflammatory phenotype associated with CAD progression is unknown.
39 ing site (here named EACBE) in dynamic chromatin regulation is unknown.
40 ist within kidney transplants or play any role in rejection is unknown, however, in part because of limited techniques fo
41 ce on the antigen-specific T cell receptor (TCR) repertoire is unknown.
42 ntial role driving or regulating active avoidance responses is unknown.
43 RC contributes to transcription regulation in Ewing sarcoma is unknown.
44  (CNS) innate immune cells contributing to oxidative stress is unknown, and therapies to target their neurotoxic function
45 e a meaningful impact on cardiovascular health and survival is unknown.
46 s of COPD, including increased exacerbation susceptibility, is unknown.
47 ng, with relaxed eligibility criteria and bridging therapy, is unknown.
48 ure-while reducing the need for red blood cell transfusions-is unknown.
49 ructurally defined; however, the efficacy of h5B3.1 in vivo is unknown.
50     Why some AIV lineages but not others evolve in this way is unknown.